Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cytokine concentration across the stratum corneum in atopic dermatitis and healthy controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Simvastatin improves mitochondrial respiration in peripheral blood cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Independent evolution of cutaneous lymphoma subclones in different microenvironments of the skin

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systemisk toksicitet ved lokalanalgetika

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA1c in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA1c-values <42 mmol/mol (<6%), and 1% had critically low Hba1c values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA1c within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA1c-values suggesting overtreatment.

Original languageEnglish
Article number4095
JournalScientific Reports
Volume10
Issue number1
Pages (from-to)4095
ISSN2045-2322
DOIs
Publication statusPublished - 1 Dec 2020

ID: 59565474